Kodiak Sciences Inc. (KOD)

3,7700 +0,0700 (+1,89%) Alla chiusura: 04:00PM EDT

Kodiak Sciences Inc.

1200 Page Mill Road
Palo Alto, CA 94304
United States
650 281 0850
https://kodiak.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 111

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Victor Perlroth M.D.	Co-Founder, Chairman, CEO & President	1,18M	N/D	1974
Mr. John A. Borgeson CPA, M.B.A.	Executive VP, CFO & Secretary	720,49k	N/D	1963
Dr. Hong Liang Ph.D.	Senior Vice President of Discovery Medicine	300,71k	N/D	1972
Dr. Stephen Raillard Ph.D.	Senior Vice President of Chemical Development & Manufacturing	N/D	N/D	N/D
Ms. Almas Qudrat M.Sc.	Senior Vice President of Quality Operations	N/D	N/D	N/D
Dr. J. Pablo Velazquez-Martin M.D.	Senior Vice President of Clinical Research & Development	N/D	N/D	N/D
Ms. Tracy Chien	VP & Corporate Controller	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Governance aziendale

L'ISS Governance QualityScore di Kodiak Sciences Inc. al 1 maggio 2024 è 9. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 9; diritti degli azionisti: 8; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.